BCL2 and acute myeloid leukemia: We hypothesized that alvocidib would synergize with BCL-2 inhibitor venetoclax in AML through complementary mechanisms, namely decreased MCL-1 and increased BIM, to modulate the overall balance of anti- and pro-apoptotic BCL-2 family proteins in favor of apoptosis induction.